Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Duo

Financiado

Cerrado

Duo A minimally invasive device to treat all patients with tricuspid valve dise...

Duo A minimally invasive device to treat all patients with tricuspid valve disease Heart failure is the leading cause of death, affecting 15 million patients across Europe and the US. In patients with heart failure, the right heart expands, resulting in the tricuspid valve not closing properly and blood leaking... ver más

30/11/2023

CROIVALVE

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

CROIVALVE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-11-30

EIC-FTI-2018-2020: Fast Track to Innovation (FTI)

I+D

Cerrada hace 6 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

CROIVALVE

1.90M€ | Lider

SAT NUMERO 8275 QUESOS FLOR...

217.19K€ | Participante

ICS Med Devices

480.18K€ | Participante

Syntactx Europe

460.11K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Trillium A transcatheter functional valve replacement for tricuspid v... 6M€ Cerrado

Trisol System A safe and effective replacement valve for treating severe T... 3M€ Cerrado

CVTVT A Non Surgical Treatment to Restore Heart Valve Function 5M€ Cerrado

TRICARIX Minimally invasive transcatheter system for tricuspid heart... 4M€ Cerrado

TriSol System A heart valve prosthesis and delivery system intended to rep... 71K€ Cerrado

Heart Function Support Innovative, minimally invasive device to support the natural... 26M€ Cerrado

Duración del proyecto: 42 meses Fecha Inicio: 2020-05-13
Fecha Fin: 2023-11-30

Líder del proyecto

CROIVALVE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Heart failure is the leading cause of death, affecting 15 million patients across Europe and the US. In patients with heart failure, the right heart expands, resulting in the tricuspid valve not closing properly and blood leaking backwards. This is called tricuspid regurgitation. The tricuspid valve has remained largely untreated due to unique functional and anatomical challenges. Currently less than 1% of patients are surgically treated due to the fact that open-heart surgery is still the only treatment option and is very risky. As a result, these patients face worsening quality of life with 60% of patients not surviving past 3 years. The Duo project aims to enable the commercialisation of a minimally invasive device that restores the function of the tricuspid valve in a safe and effective manner for all patients with TR. An innovative adjustable anchor holds the device in position between the tricuspid valve leaflets, anchored against the venous wall, where it does not touch the fragile cardiac tissue. This multi-disciplinary consortium of innovative SME’s is uniquely positioned to accelerate bringing this disruptive technology to market. CroiValve, the consortium coordinator, was founded specifically to develop and commercialise a minimally invasive tricuspid treatment. ICS Medical is an expert in the design, development and manufacturing of complex catheter solutions. Syntactx is a full-service CRO that understands how to deliver efficient and good quality clinical data. 3D LaserTec is an innovation driven centre for laser cut parts. With Fast Track to Innovation funding, the consortium will finalise the development of the Duo-TF device and develop US clinical evidence demonstrating the clinical benefits of Duo to the patient. This will position Duo as the gold standard treatment, thus saving the lives of thousands of patients and reducing this significant healthcare burden. The project will also enable Europe to take the lead in the large tricuspid €2.5Bn/year market.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores